Learn about the specifics of treating non-small cell lung cancer (NSCLC) when a KRAS mutation is present. The KRAS gene, often mutated in several cancers including NSCLC, signals cells to proliferate uncontrollably. The video emphasizes the importance of biomarker testing, which can detect KRAS mutations and guide the treatment strategy. It highlights targeted therapies like KRAS G12C inhibitors, which can significantly impact tumor growth in affected individuals. This presentation also discusses the relevance of clinical trials and encourages consulting with healthcare providers to explore potential treatments tailored to KRAS mutations.